11 Nov 2015 07:00
For immediate release | 11 November 2015 |
NANOCO GROUP PLC
("Nanoco" or the "Company")
Appointment of Non-executive Director
Nanoco Group plc (LSE: NANO), a world leader in the development and manufacture of cadmium-free quantum dots and other nanomaterials, is pleased to announce the appointment of Christopher Richards PhD as a Non-executive Director of the Company with effect from 11 November 2015. As part of his role, Christopher will chair the Nominations Committee and will also be a member of the Audit and Remuneration Committees.
Following a successful international career in the agrochemicals and life sciences industries, Christopher has become a highly experienced non-executive director and business adviser.
He currently holds a number of executive and non-executive roles at quoted and private businesses. He is the executive chairman of Plant Health Care plc (AIM: PHC) and a non-executive director of Dechra Pharmaceuticals plc (LSE: DPH) and of Origin Enterprises plc (AIM: OGN). He is also a non-executive director at Cibus Global Inc, a privately owned US biotechnology company, and the founder of Talestris Ltd, his consultancy business.
Christopher is the former chief executive officer of Arysta LifeScience, a Japan-based agrochemicals business which grew rapidly under his leadership. After stepping down as chief executive officer in 2009, he became Arysta LifeScience's non-executive chairman until the sale of the business earlier this year to Platform Specialty Products.
Christopher began his executive career in 1983 at Imperial Chemical Industries plc in the crop science division, which became Syngenta. During 20 years, he lived in countries including Colombia and Japan in roles including Syngenta's global product portfolio manager and marketing head for EMEA.
Anthony Clinch, Nanoco's Chairman, said: "We are delighted to welcome Dr Christopher Richards to the Nanoco Board as a Non-executive Director. His wide ranging business experience, and particularly his experience in biotechnology and life sciences, will be invaluable as we drive the commercialisation of our technology in multiple target markets."
As at 10 November 2015, Christopher had a beneficial interest in 43,421 shares in Nanoco. Of these shares 17,544 are held by his wife, Ann Carolyn Richards.
Save as disclosed above, there is no information to be disclosed in respect of Christopher Richards pursuant to paragraph 9.6.13 of the UKLA's Listing Rules.
For further information, please contact:
Nanoco | Tel: +44 (0) 161 603 7900 |
Michael Edelman, Chief Executive Officer | |
David Blain, Chief Financial Officer Caroline Watson, Investor Relations Manager cwatson@nanocotechnologies.com |
Tel: + 44 (0) 7799 897357 |
Canaccord Genuity - Joint Broker | Tel: +44 (0) 20 7523 8000 |
Simon Bridges Cameron Duncan | |
Mark Whitmore | |
Liberum - Joint Broker | Tel: +44 (0) 20 3100 2000 |
Neil Patel | |
Richard Bootle Steven Tredget | |
Buchanan | Tel: +44 (0) 20 7466 5000 |
Mark Court / Sophie Cowles / Stephanie Watson |
Notes for editors:
About Nanoco Group plc
Nanoco is a world leader in the development and production of cadmium-free quantum dots and other nano-materials for use in multiple applications including LCD displays, lighting, solar cells and bio-imaging. In the display market, it has an exclusive manufacturing and marketing licensing agreement with The Dow Chemical Company.
Nanoco was founded in 2001 and is headquartered in Manchester, UK. It has production facilities in Runcorn, UK, and a US subsidiary, Nanoco Inc, based in Concord, MA. Nanoco also has business development executives in Japan, Korea and Taiwan. Its technology is protected worldwide by a large and growing patent estate.
Nanoco is listed on the main market of the London Stock Exchange and trades under the ticker symbol NANO. For further information please visit: www.nanocogroup.com.
Nanoco (NANO)